SCHEMBL138768

SCHEMBL138768

Cc1ccc2nc(Nc3cc(Cc4ccccc4)nc(Nc4ccc(CC(=O)O)cc4F)n3)sc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 11/20 0.59
LCK P06239 11/20 0.59
ITK Q08881 10/20 0.59
EGFR P00533 1/20 0.52
INSR P06213 1/20 0.52
SRC P12931 1/20 0.52
TEC P42680 1/20 0.52
TXK P42681 1/20 0.52
BMX P51813 1/20 0.52
BTK Q06187 1/20 0.52
LRRK2 Q5S007 1/20 0.52
CAMKK2 Q96RR4 1/20 0.52
IRAK4 Q9NWZ3 1/20 0.52
CSNK1D P48730 1/20 0.45
KMT2A Q03164 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 2/20 0.43
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141967 0.94 AURKB (0.60) AURKBLCKITKEGFRINSR
SCHEMBL178945 0.90 LCK (0.61) AURKBLCKITKEGFRINSR
SCHEMBL10270846 0.86 LCK (0.65) AURKBLCKITKEGFRINSR
SCHEMBL137782 0.83 LCK (0.60) AURKBLCKITKEGFRINSR
SCHEMBL140736 0.81 AURKB (0.64) AURKBLCKITKEGFRINSR
SCHEMBL178858 0.80 LCK (0.61) AURKBLCKITKEGFRINSR
SCHEMBL140143 0.80 AURKB (0.65) AURKBLCKITKEGFRINSR
SCHEMBL146639 0.78 AURKB (0.57) AURKBLCKITKEGFRINSR
SCHEMBL143034 0.78 AURKB (0.59) AURKBLCKITKEGFRINSR
SCHEMBL138299 0.78 AURKB (0.52) AURKBLCKITKEGFRINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK AURKB 53/4885LCK 189/4885ITK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.